Shuji Murakami

Yokohama, 2418515, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 113 publications

Comparison of Amplicon-Based Next-Generation Sequencing Testing and Immunohistochemical Staining in Detecting Anaplastic Lymphoma Kinase Fusion Genes in Non-Small-Cell Lung Cancer: A Large Single-Centre Cohort Study.

Comparison of Amplicon-Based Next-Generation Sequencing Testing and Immunohistochemical Staining in Detecting Anaplastic Lymphoma Kinase Fusion Genes in Non-Small-Cell Lung Cancer: A Large Single-Centre Cohort Study.

Journal: Cancers

Published: June 03, 2026

Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP.

Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP.

Journal: Frontiers in immunology

Published: March 17, 2026

Gefitinib response after acquisition of C797S following first-line osimertinib in EGFR L858R/E709K-mutated non-small cell lung cancer: A case report.

Gefitinib response after acquisition of C797S following first-line osimertinib in EGFR L858R/E709K-mutated non-small cell lung cancer: A case report.

Journal: Respiratory investigation

Published: February 01, 2026

Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With EGFR Mutation (West Japan Oncology Group 11719L: ADJUST Study).

Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With EGFR Mutation (West Japan Oncology Group 11719L: ADJUST Study).

Journal: JTO clinical and research reports

Published: November 13, 2025

Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial.

Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 18, 2025

Clinical Utility of Comprehensive Genomic Profiling for Advanced Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.

Clinical Utility of Comprehensive Genomic Profiling for Advanced Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.

Journal: Thoracic cancer

Published: September 22, 2025

Utility of AMOY polymerase chain reaction panel in detecting non-small cell lung cancer using pleural cell block.

Utility of AMOY polymerase chain reaction panel in detecting non-small cell lung cancer using pleural cell block.

Journal: Japanese journal of clinical oncology

Published: September 04, 2025

Impact of Phrenic Nerve Repair Using Intercostal Nerve Graft on Diaphragm Function after Thoracic Tumour Resection.

Impact of Phrenic Nerve Repair Using Intercostal Nerve Graft on Diaphragm Function after Thoracic Tumour Resection.

Journal: Interdisciplinary cardiovascular and thoracic surgery

Published: August 31, 2025

Machine learning-based insights into circulating autoantibody dynamics and treatment outcomes in patients with NSCLC receiving immune checkpoint inhibitors.

Machine learning-based insights into circulating autoantibody dynamics and treatment outcomes in patients with NSCLC receiving immune checkpoint inhibitors.

Journal: Frontiers in immunology

Published: July 15, 2025

Quinolinic acid as trigger/biomarker of dysosmia/dysgeusia in patients with acute coronavirus disease 2019: A retrospective case-control study.

Quinolinic acid as trigger/biomarker of dysosmia/dysgeusia in patients with acute coronavirus disease 2019: A retrospective case-control study.

Journal: Brain, behavior, & immunity - health

Published: July 03, 2025

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 02, 2025

Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors.

Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors.

Journal: Clinical lung cancer

Published: April 10, 2025

Showing 1-12 of 113

Last Updated: 09/26/2026